- Product Now Being Sold in 14 Countries Worldwide -
LAVAL, QC, July 31 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its once-daily formulation of tramadol has been launched in the following countries:
South Korea - Labopharm's marketing partner for South Korea, WhanIn Pharmaceutical Co. Ltd., launched the product in July under the brand name TramaConti CR(R).
Australia - Labopharm's marketing partner for Australia, iNova Pharmaceuticals (Australia) Pty Limited launched the product in July under the brand name Durotram XR(R).
Romania - Labopharm's marketing partner for Romania, CSC Pharmaceuticals, launched the product in July under the brand name Noax(R) Uno.
Austria - Labopharm's marketing partner for Austria, CSC Pharmaceuticals, launched the product in June under the brand name Noax(R) Uno.
"With these launches, our once-daily tramadol product is now being sold in 14 countries that, combined, account for almost 55% of the world's market for tramadol products," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "South Korea and Australia, in particular, represent significant opportunities as the 6th and 12th largest markets for tramadol products in the world, respectively. We look forward to leveraging the experience we have gained through our previous European and Canadian launches and working with our marketing partners to maximize our product's potential in these markets."
Labopharm's product is available in 100mg, 200mg and 300mg dosage strengths in Australia, Austria and Romania and in 100mg and 200mg dosage strengths in South Korea. The 300 mg dosage strength is approved for sale in South Korea and may be marketed at a later date.
About Labopharm's Once-Daily Tramadol Product
Labopharm's once-daily tramadol product is based on the Company's
proprietary Contramid(R) technology, which provides a dual matrix delivery
|SOURCE Labopharm Inc.|
Copyright©2008 PR Newswire.
All rights reserved